SLC5A2 and type 1 diabetes mellitus: However, restrictions in the use of SGLT2 inhibitors have been widely reported, and adverse outcomes include increased occurrence of genital mycotic infections [65,66] and euglycaemic DKA in patients with T1DM and T2DM [66,67].